
|Articles|June 1, 2003
Moxifloxacin gains FDA approval
Author(s)Lynda Charters
Dallas-Moxifloxacin ophthalmic solution (Vigamox 0.5%, Alcon Laboratories) was approved by the FDA on April 16 for the treatment of bacterial conjunctivitis, following a 6-month review of the drug.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought echanisms
2
Midyear cataract check-in: What 2026 has brought to the OR and beyond
3
Durability With Aflibercept 8 mg in Retinal Vascular Diseases
4
Next-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
5





















